
==== Front
BMC Chem
BMC Chem
BMC Chemistry
2661-801X
Springer International Publishing Cham

39252071
1272
10.1186/s13065-024-01272-6
Research
Investigation of green synchronous spectrofluorimetric approach for facile sensitive estimation of two co-administered anti-cancer drugs; curcumin and doxorubicin in their laboratory-prepared mixtures, human plasma, and urine
Dagher Diaa diaadagher@mans.edu.eg

1
Elmansi Heba 1
Nasr Jenny Jeehan 12
El-Enany Nahed 13
1 https://ror.org/01k8vtd75 grid.10251.37 0000 0001 0342 6662 Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 35516 Egypt
2 Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Mansoura National University, Gamasa, 7723730 Egypt
3 https://ror.org/05km0w312 0000 0005 0814 6423 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, New Mansoura University, New Mansoura, 7723730 Egypt
9 9 2024
9 9 2024
12 2024
18 1 16430 5 2024
16 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Recently, phytochemicals play an important role in cancer management. Curcumin (CUR), a natural phytochemical, has been co-administered with widespread chemotherapeutic agents such as doxorubicin (DOX) due to its excellent antitumor activity and the ability to lower the adverse reactions and drug resistance cells associated with DOX use. The present study aims to determine DOX and CUR utilizing a label-free, selective, sensitive, and precise synchronous spectrofluorimetric method. The obvious overlap between the emission spectra of DOX and CUR prevents simultaneous estimation of both analytes by conventional spectrofluorimetry. To solve such a problem, synchronous spectrofluorimetric measurements were recorded at Δλ = 20 nm, utilizing ethanol as a diluting solvent. Curcumin was recorded at 442.5 nm, whereas DOX was estimated at 571.5 nm, each at the zero-crossing point of the other one. The developed method exhibited linearity over a concentration range of 0.04–0.40 μg/mL for CUR and 0.05–0.50 μg/mL for DOX, respectively. The values of limit of detection (LOD) were 0.009 and 0.012 µg/mL, while the values of limit of quantitation (LOQ) were 0.028 and 0.037 µg/mL for CUR and DOX, respectively. The adopted approach was carefully validated according to the guidelines of ICH Q2R1. The method was utilized to estimate CUR and DOX in laboratory-prepared mixtures and human biological matrices. It showed a high percentage of recoveries with minimal RSD values. Additionally, three different tools were utilized to evaluate the greenness of the proposed approach.

Keywords

Curcumin
Doxorubicin
Synchronous spectrofluorimetric
Biological matrices
Greenness
Mansoura UniversityOpen access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

issue-copyright-statement© Springer Nature Switzerland AG 2024
==== Body
pmcIntroduction

Chemotherapy with antitumor medications is crucial in the clinical treatment of cancer. However, these medications have serious side effects, and the cancer cells may develop drug resistance that could lower chemotherapy’s effectiveness or even stop it [1, 2]. Since some phytochemicals have such strong anticancer action, they could be used in combination with chemotherapeutic drugs in cancer treatment. Additionally, phytochemicals are safer and more favorable than chemotherapy which has unwanted side effects [3, 4].

Doxorubicin (DOX, Fig. 1A) hydrochloride, an anthracycline glycoside, is chemically named (8S,10S)-10-[(3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride. DOX is frequently used to treat several malignancies, such as ovarian cancer, breast cancer, lung cancer, and malignant lymphoma [5, 6]. Its mechanism of action depends on the intercalation of DOX with the DNA double helix so that it inhibits transcription as well as replication of cancer cell DNA [7, 8]. Owing to the potential adverse reactions such as cardiotoxicity and subsequent congestive heart failure, the long-term clinical use of DOX is restricted [9, 10]. To avoid this problem, various strategies could be adopted such as using a natural product that decreases side effects and reduces cancer cells’ drug-resistance [11]. The literature survey of DOX revealed different assay methods such as spectrophotometric [12, 13], HPLC [12, 13], spectrofluorimetric [14–17], and electrochemical [18–20] methods.Fig. 1 Structural formulae of DOX (A) and CUR (B)

Curcumin (CUR, Fig. 1B) is the polyphenolic bioactive component of Curcuma longa rhizome. CUR is chemically named (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione. CUR is commonly used as a food coloring agent due to its yellow color, preservative, and spice in cooking [21]. It has an impressive role in medicine by its antioxidant [22], antiproliferative [23], anti-inflammatory [24], immunomodulatory [25], antidiabetic [26], and antitumor [27] activity. Several methods for the assay of CUR have been published such as HPLC [28, 29], spectrophotometric [30, 31], spectrofluorimetric [32–35], and electrochemical [36–38] methods.

Curcumin, an important natural phytochemical, has been reported to be used in combination chemotherapy with doxorubicin [11, 39]. Curcumin increases the efficacy of DOX on cancer cells, decreases the side effects of DOX, and reverses the chemoresistance of DOX [39, 40].

Although both DOX and CUR were determined separately by various methods, only two HPLC approaches were reported for simultaneous estimation of both DOX and CUR [41, 42]. These HPLC methods [41, 42] had many disadvantages, such as complicated sample preparation, long chromatographic run times, and using environmentally hazardous solvents such as acetonitrile in the mobile phase. Up till now, no spectrofluorimetric approaches have been published for simultaneous estimation of both DOX and CUR. Considering that spectroscopic methods are the most widespread analytical techniques due to their simplicity and availability compared with chromatographic methods. The primary aim of the presented work is to validate a simple, rapid, reliable, ultra-sensitive, and selective spectrofluorimetric approach used for concurrent determination of both CUR and DOX in their laboratory-prepared mixtures, spiked human plasma and urine. The overlapped spectra produced from the direct measurements of the native fluorescence of both analytes were resolved by employing synchronous fluorescence spectroscopy (SFS) mode [43–47]. Three different tools were utilized to ensure the proposed approach’s greenness. The utilized three tools were the National Environmental Method Index (NEMI) [48], analytical ecoscale [49], and AGREE metric approach [50].

Experimental

Instrumentation

A Cary Eclipse fluorescence spectrophotometer was utilized for all measurements. It was equipped with an 800-V xenon lamp. Furthermore, the selected slit width was 5 nm with a smoothing factor of 20, and the utilized Δλ was Δλ = 20 nm. Helma® fluorescence quartz cuvette cell was used for sample measurement.

For the pH adjustment, a Consort pH meter (model NV P-901, Belgium) was utilized. A glass electrode was attached to the pH meter which contained Ag/AgCl reference electrode.

For sonication, Sonic IV model-SS101H 230 (USA) was utilized.

For biological fluids preparation, a vortex mixer (model IVM-300P, Taiwan) and a centrifuge (model 2-16P, Germany) were used.

Reagents and materials

Doxorubicin (99.85%) was obtained from Selleckchem (Houston, USA).

Doxorubicin ‘Ebewe’ ® ampule 50 mg/25 mL batch # KV0787, EBEWE Pharma Ges.m.b.H.Nfg.KG A-4866 Unterach, Austria.

Curcumin (99.0%) was purchased from EMITCO Pharmaceuticals (Alexandria, Egypt).

Organic solvents (HPLC grade) such as acetonitrile, methanol, and ethanol were obtained from Sigma‐Aldrich, Germany.

Sodium hydroxide, boric acid, acetic acid, phosphoric acid, β-cyclodextrin, carboxy methyl cellulose (CMC), sodium dodecyl sulfate (SDS), and Tween 80, were obtained from Sigma‐Aldrich, Germany.

Human plasma samples utilized in this study were generously supplied by Mansoura University Hospital. These plasma samples were kept in the freezer till the analysis time.

Fresh urine samples were donated by a 50-year-old drug-free, healthy male volunteer and were kept in the freezer till the analysis time.

Standard solutions and buffer solutions

Stock solutions (100 μg/mL) were prepared in 100 mL volumetric flasks by separately dissolving 10 mg of CUR in ethanol, and then completed to the mark with ethanol, while 10 mg of DOX was dissolved in distilled water then completed to the mark with distilled water. After that, the prepared solutions were diluted to obtain the working solutions with a concentration of 10 μg/mL for both DOX and CUR.

Britton Robinson buffer (BRB) solution was prepared by mixing equimolar concentrations (0.4 M) of boric acid, acetic acid, and phosphoric acid. After that, the pH was adjusted utilizing 0.2 M sodium hydroxide, resulting in a series of solutions covering a pH range of 2–12.

Construction of calibration curves procedures

The experimental procedure involved transferring specified volumes of each of DOX and CUR working solutions (10 μg/mL) into a set of 10 mL volumetric flasks, then diluted with ethanol to the mark and mixed well to obtain the final concentration range 0.05–0.50 μg/mL for DOX and 0.04–0.40 μg/mL for CUR. Afterward, SFS of the prepared solutions was measured at Δλ = 20 nm for each analyte. The synchronous fluorescence intensities were recorded for CUR and DOX against ethanol blank at 442.5 nm and 571.5 nm, respectively. All measurements were made at room temperature 25 ± 2 °C. After that, the calibration graphs were conducted by plotting the relative synchronous fluorescence intensity (RSFI) versus the corresponding final concentrations of each drug in μg/mL. Following that, the regression equations were generated using the data obtained from the calibration curves.

Procedures for analysis of DOX/CUR in their laboratory-prepared mixtures

In a 100 mL volumetric flask, a stock solution (100 μg/mL) of DOX was prepared by dissolving 5 mL of Doxorubicin ‘Ebewe’ ® ampule 50 mg/25 mL into 50 mL distilled water, mixed well, and diluted to the mark with distilled water. After that, further dilution was made to prepare a 10 μg/mL working solution. Variable aliquots from DOX and CUR working solutions (10 μg/mL) were quantitatively transferred to a series of 10 mL volumetric flasks to prepare four laboratory-prepared mixtures with variable ratios of (2:1), (1:3), (1:2), and (4:3), respectively. After that, the flasks were completed with ethanol to the mark. The procedure was then followed as cited in “Construction of calibration curves procedures” section.

Procedures for DOX/CUR analysis in spiked biological fluids

Two different sets of 15.0 mL centrifugation tubes were used to spike 1 mL of human plasma or urine separately with varying volumes of DOX and CUR working solutions. For the plasma samples, the final concentrations of DOX and CUR were 0.1–0.5 μg/mL and 0.05–0.4 μg/mL, respectively. For the urine samples, the concentrations were 0.2–0.5 μg/mL and 0.1–0.4 μg/mL, respectively. All tubes were mixed well and diluted with acetonitrile, a protein precipitating agent, to 10.0 mL. After that, each tube was subjected for 1 min to a vortex, and then it was centrifuged at a speed of 4000 rpm for 20 min. Subsequently, the clear supernatants were subjected to filtration utilizing 0.45 μm syringe filters. The next step was to sequentially transfer aliquots of 1 mL of the filtered supernatants into a series of 10.0 mL volumetric flasks, and after that, each flask was completed to the mark with ethanol. All synchronous spectrofluorimetric measurements were carried out along with blank plasma or urine samples and the diluting solvent was ethanol. The calibration graphs and regression equations were then derived.

Results and discussion

Doxorubicin and curcumin showed strong native fluorescence at 595 and 535 nm after excitation at 495 nm and 420 nm for DOX and CUR, respectively, as abridged in Fig. 2. However, the emission spectra of CUR and DOX were highly overlapped which makes their simultaneous determination quite difficult. Consequently, the simultaneous measurement of both analytes in biological matrices via conventional fluorescence spectroscopy represents a significant challenge. Hence, the SFS approach was the best choice for analyzing these two analytes with high selectivity and minimal interference. Different Δλ in the range of (20–200 nm) were studied to choose the best optimum Δλ for the resolution of the studied mixture. It was noticed that Δλ = 20 nm yielded the optimal results in terms of getting resolved spectra for each analyte while avoiding any interference from the other one (Fig. 3). After using SFS method at Δλ = 20 nm, it was found that the SFS spectra of various concentrations of CUR were recorded at 442.5 nm in the presence of a fixed concentration of DOX (0.3 μg/mL) (Fig. 4A), while various concentrations of DOX were recorded at 571.5 nm in the presence of a fixed concentration of CUR (0.4 μg/mL) (Fig. 4B).Fig. 2 Excitation and emission fluorescence spectra of CUR (0.2 µg/mL) (a, a′) and DOX (0.5 µg/mL) (b, b′) in ethanol (c, c′)

Fig. 3 Synchronous fluorescence spectra of (a) CUR (0.4 µg/mL) and (b) DOX (0.3 µg/mL) in (c) ethanol (blank solvent)

Fig. 4 A Synchronous fluorescence spectra of (1) DOX (0.3 µg/mL) and (2) CUR (a–e: 0.04, 0.1, 0.2, 0.3, and 0.4 µg/mL) at 442.5 nm. B Synchronous fluorescence spectra of (1) CUR (0.4 µg/mL) and (2) DOX (a–f: 0.05, 0.1, 0.2, 0.3, 0.4, and 0.5 µg/mL) at 571.5 nm

The suggested approach optimization

Different parameters affecting the fluorescence intensity of both DOX and CUR were thoroughly examined. Each parameter is optimized separately, while the others are kept constant.

Effect of diluent

The impact of different diluents was investigated in order to choose the best one yielding the highest fluorescence intensity. Four solvents, including methanol, water, acetonitrile, and ethanol were examined.

Using ethanol as the diluting solvent for both analytes exhibited the highest fluorescence intensities (Fig. 5A). Ethanol has the additional advantage of being a green and eco-friendly solvent so it is the best one of choice to be used for the suggested method.Fig. 5 A The effect of diluting solvents. B The effect of pH. C The effect of surfactants and macromolecules

Effect of pH of buffer solutions

The impact of pH on the fluorescence intensity of DOX and CUR was investigated utilizing BRB (pH range: 2–12). Neither DOX nor CUR showed a significant increase in fluorescence intensity in the studied range of pH as shown in Fig. 5B. Consequently, the present study was carried out without using any buffer solutions.

Effect of surfactants and macromolecules

The surfactant study was conducted to further enhance the sensitivity of the proposed method and reach lower limits of detection [51]. The impact of different surfactants (1.0% w/v) such as sodium dodecyl sulfate (SDS), Tween 80, carboxy methyl cellulose (CMC), or macromolecules such as β-cyclodextrin on the fluorescence intensity of DOX and CUR was carried out. It was observed that none of the specified surfactants or macromolecules significantly increased the fluorescence intensity of the two analytes as abridged in Fig. 5C. It can be explained that the bulkiness of the two analytes inhibits their inclusion in the micelles of organized media. Therefore, the proposed approach was carried out utilizing ethanol without any surfactants or macromolecules.

The optimum Δλ selection

Both DOX and CUR were recorded at Δλ intervals between 20 and 160 nm to select the best Δλ that gives peaks with high resolution and sensitivity. The ideal Δλ at which the highest selectivity and sensitivity were attained for both analytes was found to be Δλ = 20 nm (Fig. 3).

Validation

The suggested approach was validated following the (ICH) Q2R1 guidelines for validation of analytical procedures [52].

Concerning the linearity of the suggested approach, it was linear throughout the final concentration range of 0.05–0.50 µg/mL and 0.04–0.40 µg/mL for DOX and CUR, respectively, and the regression data was abridged in Table 1. The linearity was established by the high values of the correlation coefficient (r > 0.999) for both drugs [53]. The sensitivity of the proposed approach was assessed by the calculation of limit of detection (LOD) and limit of quantitation (LOQ). The LOD and LOQ were calculated with the following equations in accordance with the (ICH) Q2R1 recommendations [52]:LOD=3.3S,LOQ=10S,

where σ is the standard deviation of intercept and S is the slope.Table 1 Analytical performance data for the proposed method

Parameter	DOX	CUR	
Wavelength difference	Δλ= 20 nm	
Linearity range (μg/mL)	0.05–0.50	0.04–0.40	
Intercept (a)	7.32	− 25.94	
Slope (b)	1927.78	1339.42	
Correlation coefficient (r)	0.9997	0.9998	
S.D. of residuals (Sy/x)	9.08	4.39	
S.D. of intercept (Sa)	7.07	3.69	
S.D. of slope (Sb)	23.30	15.06	
Percentage relative standard deviation, % RSD	1.19	1.55	
% Error	0.49	0.69	
Limit of detection, LOD (µg/mL)	0.012	0.009	
Limit of quantitation, LOQ (µg/mL)	0.037	0.028	

The values of LOD were 0.012 and 0.009 µg/mL, while the values of LOQ were 0.037 and 0.028 µg/mL for DOX and CUR, respectively.

The accuracy of the suggested approach was assessed by performing a comparative analysis between the results obtained from the proposed approach and those of the reported approaches [16, 33]. The comparison method [16] for DOX involved the measurements of the native fluorescence of DOX at 590 nm after excitation at 475 nm using 0.5 mL of 0.5 M HCl as a diluting solvent and the volume was completed to the mark with ethanol. The comparison method [33] for CUR involved the measurements of the native fluorescence of CUR at 527 nm after excitation at 423 nm using methanol as a diluting solvent at a concentration range of 0.05–0.50 μg/mL. The statistical analysis results acquired through the utilization of Student’s t-test and variance ratio F-test showed no significant difference between the suggested approach and the reported approaches [53] as abridged in Table 2.Table 2 Assay results for the determination of DOX and CUR in their pure forms by the proposed and comparison methods

Studied drugs	Proposed method	Comparison methods [16, 33]	
Conc. taken (μg/mL)	Conc. found (μg/mL)	% Founda	Conc. taken (μg/mL)	% Founda	
DOX	0.05	0.050	100.00	0.2	99.50	
0.1	0.101	101.00	0.5	100.40	
0.2	0.197	98.50	0.8	99.88	
0.3	0.299	99.67		
0.4	0.407	101.75	
0.5	0.496	99.20	
Mean ± S.D		100.02 ± 1.19	99.93 ± 0.45	
t-test	0.16 (2.37)*		
F-test	6.99 (19.30)*	
CUR	0.04	0.040	100.00	0.1	99.00	
0.1	0.102	102.00	0.2	101.00	
0.2	0.196	98.00	0.4	99.75	
0.3	0.304	101.33		
0.4	0.399	99.75	
Mean ± S.D		100.22 ± 1.55	99.92 ± 1.01	
t-test	0.33 (2.45)*		
F-test	2.36 (19.25)*	
*The figures between parentheses are the tabulated t and F values at P = 0.05 [53]

aEach result is the average of three separate determinations

Intra-day and inter-day precision of the suggested approach were investigated for both DOX and CUR using three different concentrations three times within 1 day (intra-day precision) or within 3 different days (inter-day precision). High precision was confirmed by the relatively minimal values of percentage RSD (< 2.0) and percentage error (< 1.0) for both drugs (Table 3).Table 3 Precision data for the determination of DOX and CUR pure forms by the proposed method

Conc (μg/mL)	DOX	CUR	
0.1	0.3	0.5	0.1	0.3	0.4	
Intraday	% Founda	100.30	100.57	99.83	100.67	99.23	100.22	
98.81	99.54	99.73	98.54	101.13	99.67	
100.89	100.00	100.46	100.14	99.64	99.94	
Mean	100.00	100.04	100.01	99.78	100.00	99.94	
S.D	1.07	0.51	0.39	1.11	1.00	0.28	
% RSD	1.07	0.51	0.39	1.11	1.00	0.28	
% Error	0.62	0.29	0.23	0.64	0.58	0.16	
Interday	% Found	101.00	100.67	99.80	101.00	99.30	100.75	
102.00	99.67	99.20	102.00	101.33	99.70	
99.00	99.33	98.80	99.700	100.67	100.50	
Mean	100.67	99.89	99.27	100.90	100.43	100.32	
S.D	1.53	0.70	0.50	1.15	1.04	0.55	
% RSD	1.52	0.70	0.50	1.15	1.04	0.55	
% Error	0.88	0.40	0.29	0.66	0.60	0.32	
aEach result is the average of three separate determinations

The robustness of the proposed approach was assessed by investigating the minor changes that could affect the fluorescence intensity such as Δλ = 20 ± 5 nm. These minor changes revealed no significant alteration in the proposed approach performance.

The selectivity was assessed for the proposed approach by the determination of DOX and CUR in various ratios of their laboratory-prepared mixtures, as shown in Fig. 6. At 571.5 nm, DOX was recorded without any CUR interference. At 442.5 nm, CUR was measured where DOX showed no interference. The selectivity was assessed by the excellent % recovery and low values of %RSD (< 2%) (Table 4). Additionally, the selectivity of the suggested approach was established by estimation of CUR and DOX in spiked human plasma and urine. It was found that the proposed approach showed low SD values for both analytes (Table 5).Fig. 6 Synchronous fluorescence spectra of (a) CUR (0.3 µg/mL), (b) DOX (0.3 µg/mL), and (c) synthetic mixture of both

Table 4 Assay results for the determination of DOX and CUR in synthetic mixtures by the proposed method

Mixture no.	Conc. taken (μg/mL)	Conc. taken (μg/mL)	Conc. found (μg/mL)	Conc. found (μg/mL)	% Founda	% Founda	
DOX	CUR	DOX	CUR	DOX	CUR	
1	0.4	0.2	0.407	0.203	101.97	101.83	
2	0.1	0.3	0.098	0.302	98.15	101.14	
3	0.2	0.4	0.203	0.406	101.69	100.71	
4	0.4	0.3	0.399	0.303	99.78	101.06	
Mean		100.40	101.19	
± S.D	0.79	0.47	
% RSD	0.79	0.47	
The figures between parentheses are the tabulated t and F values at P = 0.05 [53]

aEach result is the average of three separate determinations

Table 5 Assay results for the determination of DOX and CUR in spiked human plasma and urine samples

Parameters	DOX	CUR	
Conc. taken (μg/mL)	Conc. found (μg/mL)	% Founda	Conc. taken (μg/mL)	Conc. found (μg/mL)	% Founda	
Human plasma	0.1	0.098	98.00	0.05	0.049	98.00	
0.2	0.198	99.00	0.1	0.103	103.00	
0.4	0.409	102.25	0.3	0.295	98.33	
0.5	0.494	98.80	0.4	0.403	100.75	
Mean		99.51		100.02	
± S.D	1.88	2.34	
r	0.9995	0.9997	
Regression equation		RSFI = 442.68c − 23.52	RSFI = 722.9c − 9.37	
Urine	0.2	0.199	99.5	0.1	0.099	99.00	
0.4	0.407	101.75	0.3	0.308	102.67	
0.5	0.494	98.8	0.4	0.394	98.50	
Mean		100.02		100.06	
± S.D	1.54	2.28	
r	0.991	0.996	
Regression equation		RSFI = 99.29c + 91.93	RSFI = 206.79c + 53.36	
aEach result is the average of three separate determinations

Applications

Assay of DOX/CUR in laboratory-prepared mixtures

The adopted approach allowed the simultaneous estimation of CUR and DOX in their laboratory-prepared mixtures with various concentration ratios as abridged in Fig. 6. The percentage recoveries for each drug were then calculated from the regression equation for each drug. As cited in Table 4, the results confirmed the accuracy of the suggested approach.

Assay of DOX/CUR in plasma and urine samples

The adopted approach exhibits sufficient sensitivity and selectivity that enable the simultaneous quantification of CUR and DOX in human plasma or urine samples because their maximum plasma concentration (Cmax) falls within the linearity range of the suggested approach [54, 55]. As cited in Table 5, there was a linear correlation obtained when synchronous fluorescence intensity was plotted versus the concentrations of each drug in μg/mL for spiked plasma or urine matrices. The suggested method achieved high % recoveries and minimal % RSD values. These findings confirmed the high efficiency of the suggested approach in such complicated matrices as shown in Table 5.

Greenness assessment

Owing to the numerous solvents and chemicals used throughout analytical procedures, the environment is significantly influenced; as a result, it is of utmost importance to protect the environment from the waste produced by such procedures. Different three metrics were applied in this study to assess the proposed approach greenness: National Environmental Method Index (NEMI), analytical ecoscale, and AGREE evaluation method.

NEMI [48] is considered a qualitative approach, that evaluates the environmental effect of analytical procedures by employing a pictogram. This pictogram is divided into four portions. Each portion was colored green if (I) the utilized reagents not regarded to be persistent, bioaccumulative or toxic, (II) the utilized reagents are not on hazardous waste list, (III) the pH used in the proposed approach not less than 2.0 or more than 12, (IV) the waste amount generated by the suggested approach was less than 50 g per sample. Consequently, the developed method met the four criteria of greenness of NEMI tool, as abridged in Table 6.Table 6 Results for evaluation of greenness of the proposed methods

1. National Environmental Method Index (NEMI) pictogram [48]	
	
2. Analytical eco-scale score [49]				
Item	No of pictogram	Word sign	Penalty points	
(1) Reagent; volume (mL)				
 Ethanol < 10 mL	2	Danger	4	
(2) Spectrofluorimeter; < 0.1 KWh per sample			0	
(3) Occupational hazard			0	
(4) Waste			3	
Total penalty points			7	
Analytical eco-scale score			93	
3. AGREE assessment [50]	
	

Analytical eco-scale [49] is a semiquantitative tool used to evaluate the overall environmental impact of an analytical procedure. The calculation of the total penalty points in each stage is conducted by considering factors such as hazards, instrumentation energy, reagent amount, and waste. Following that, the sum of penalty points was subtracted from a value of 100, yielding the analytical eco-scale value. As shown in Table 6, the proposed approach’s score was 93, indicating the method’s excellent greenness.

AGREE [50], is a tool for assessing the proposed methods’ greenness by assessing important 12 principles. The outcome from the AGRRE pictogram indicates a score from 0 to 1. Table 6 shows that the suggested approach has a high score and satisfactory results, indicating an ‘excellent green’ method.

Conclusion

The current study aimed to propose a green synchronous spectrofluorimetric approach for the simultaneous estimation of curcumin and doxorubicin. The advantages of the suggested approach include selectivity, sensitivity, reliability, and precision. Moreover, compared with chromatographic approaches, the suggested procedure requires a short time without the need for complicated sample treatment steps. The method was optimized and validated to allow the simultaneous estimation of CUR and DOX in pure form and spiked human plasma and urine. The sensitivity of the suggested approach is superior down to 0.028 and 0.037 µg/mL for CUR and DOX, respectively, so it is considered a good choice for therapeutic drug monitoring of DOX and CUR. Furthermore, the suggested method has a low environmental effect due to the usage of a green solvent, ethanol, which is safe and eco-friendly.

Acknowledgements

Not applicable.

Author contributions

Diaa Dagher carried out the lab work, and statistical calculations. Heba Elmansi, Jenny Nasr, and Nahed El-Enany supervised the whole research and the manuscript. All authors participated in study and approved the manuscript.

Funding

Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). No funding supported this research.

Data availability

The datasets generated during and/or analysed during the current study are available in the Dryad repository: https://datadryad.org/stash/share/qVgAz5opoxEXBEGNKXP9ar_a0x9ZgCP1N4b7z7hmrAY.

Declarations

Ethics approval and consent to participate

This research was approved by the “Research Ethics Committee, Faculty of Pharmacy, Mansoura University’’ (Approval code number: 2020-12). An informed written consent was obtained from the patient whose plasma and urine were used in the research and was approved by the “Research Ethics Committee, Faculty of Pharmacy, Mansoura University”.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Anto RJ Maliekal TT Karunagaran D L-929 cells harboring ectopically expressed RelA resist curcumin-induced apoptosis J Biol Chem 2000 275 21 15601 15604 10.1074/jbc.C000105200 10747850
Anto RJ, Maliekal TT, Karunagaran D. L-929 cells harboring ectopically expressed RelA resist curcumin-induced apoptosis. J Biol Chem. 2000;275(21):15601–4.10747850 10.1074/jbc.C000105200
2. Liu X Lu Y Xu Y Hou S Huang J Wang B Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer Cancer Lett 2019 459 122 134 10.1016/j.canlet.2019.05.035 31173853
Liu X, Lu Y, Xu Y, Hou S, Huang J, Wang B, et al. Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer. Cancer Lett. 2019;459:122–34.31173853 10.1016/j.canlet.2019.05.035
3. Mu Y Wu G Su C Dong Y Zhang K Li J pH-sensitive amphiphilic chitosan-quercetin conjugate for intracellular delivery of doxorubicin enhancement Carbohydr Polym 2019 223 115072 10.1016/j.carbpol.2019.115072 31427010
Mu Y, Wu G, Su C, Dong Y, Zhang K, Li J, et al. pH-sensitive amphiphilic chitosan-quercetin conjugate for intracellular delivery of doxorubicin enhancement. Carbohydr Polym. 2019;223: 115072.31427010 10.1016/j.carbpol.2019.115072
4. Soltantabar P Calubaquib EL Mostafavi E Biewer MC Stefan MC Enhancement of loading efficiency by coloading of doxorubicin and quercetin in thermoresponsive polymeric micelles Biomacromol 2020 21 4 1427 1436 10.1021/acs.biomac.9b01742
Soltantabar P, Calubaquib EL, Mostafavi E, Biewer MC, Stefan MC. Enhancement of loading efficiency by coloading of doxorubicin and quercetin in thermoresponsive polymeric micelles. Biomacromol. 2020;21(4):1427–36.10.1021/acs.biomac.9b01742
5. Chan S Friedrichs K Noel D Pintér T Van Belle S Vorobiof D Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer J Clin Oncol 1999 17 8 2341 2354 10.1200/JCO.1999.17.8.2341 10561296
Chan S, Friedrichs K, Noel D, Pintér T, Van Belle S, Vorobiof D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999;17(8):2341–54.10561296 10.1200/JCO.1999.17.8.2341
6. Solomon R Gabizon AA Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin Clin Lymphoma Myeloma 2008 8 1 21 32 10.3816/CLM.2008.n.001 18501085
Solomon R, Gabizon AA. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin. Clin Lymphoma Myeloma. 2008;8(1):21–32.18501085 10.3816/CLM.2008.n.001
7. Jackson TL Intracellular accumulation and mechanism of action of doxorubicin in a spatio-temporal tumor model J Theor Biol 2003 220 2 201 213 10.1006/jtbi.2003.3156 12468292
Jackson TL. Intracellular accumulation and mechanism of action of doxorubicin in a spatio-temporal tumor model. J Theor Biol. 2003;220(2):201–13.12468292 10.1006/jtbi.2003.3156
8. Thorn CF Oshiro C Marsh S Hernandez-Boussard T McLeod H Klein TE Doxorubicin pathways: pharmacodynamics and adverse effects Pharmacogenet Genom 2011 21 7 440 10.1097/FPC.0b013e32833ffb56
Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genom. 2011;21(7):440.10.1097/FPC.0b013e32833ffb56
9. Ho J-A Fan N-C Jou AFJ Wu L-C Sun T-P Monitoring the subcellular localization of doxorubicin in CHO-K1 using MEKC− LIF: liposomal carrier for enhanced drug delivery Talanta 2012 99 683 688 10.1016/j.talanta.2012.06.077 22967611
Ho J-A, Fan N-C, Jou AFJ, Wu L-C, Sun T-P. Monitoring the subcellular localization of doxorubicin in CHO-K1 using MEKC− LIF: liposomal carrier for enhanced drug delivery. Talanta. 2012;99:683–8.22967611 10.1016/j.talanta.2012.06.077
10. Li Q-Q Xu J-D Wang W-J Cao X-X Chen Q Tang F Twist1-mediated adriamycin-induced epithelial–mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells Clin Cancer Res 2009 15 8 2657 2665 10.1158/1078-0432.CCR-08-2372 19336515
Li Q-Q, Xu J-D, Wang W-J, Cao X-X, Chen Q, Tang F, et al. Twist1-mediated adriamycin-induced epithelial–mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res. 2009;15(8):2657–65.19336515 10.1158/1078-0432.CCR-08-2372
11. Sadzuka Y Nagamine M Toyooka T Ibuki Y Sonobe T Beneficial effects of curcumin on antitumor activity and adverse reactions of doxorubicin Int J Pharm 2012 432 1–2 42 49 10.1016/j.ijpharm.2012.04.062 22569233
Sadzuka Y, Nagamine M, Toyooka T, Ibuki Y, Sonobe T. Beneficial effects of curcumin on antitumor activity and adverse reactions of doxorubicin. Int J Pharm. 2012;432(1–2):42–9.22569233 10.1016/j.ijpharm.2012.04.062
12. Bartzatt R Weidner E Analysis for doxorubicin by spectrophotometry and reversed phase high performance liquid chromatography (HPLC) Curr Top Anal Chem 2012 9 63 69
Bartzatt R, Weidner E. Analysis for doxorubicin by spectrophotometry and reversed phase high performance liquid chromatography (HPLC). Curr Top Anal Chem. 2012;9:63–9.
13. Scheeren LE Nogueira-Librelotto DR Fernandes JR Macedo LB Marcolino AIP Vinardell MP Comparative study of reversed-phase high-performance liquid chromatography and ultraviolet–visible spectrophotometry to determine doxorubicin in pH-sensitive nanoparticles Anal Lett 2018 51 10 1445 1463 10.1080/00032719.2017.1380034
Scheeren LE, Nogueira-Librelotto DR, Fernandes JR, Macedo LB, Marcolino AIP, Vinardell MP, et al. Comparative study of reversed-phase high-performance liquid chromatography and ultraviolet–visible spectrophotometry to determine doxorubicin in pH-sensitive nanoparticles. Anal Lett. 2018;51(10):1445–63.10.1080/00032719.2017.1380034
14. Manzoori JL Abulhassani J Niaei N Spectrofluorimetric determination of doxorubicin in spiked serum and urine samples J Chem Health Risks 2018 4 4 17 24
Manzoori JL, Abulhassani J, Niaei N. Spectrofluorimetric determination of doxorubicin in spiked serum and urine samples. J Chem Health Risks. 2018;4(4):17–24.
15. Eman I El-Yazbi AF An eco-friendly stability-indicating spectrofluorimetric method for the determination of two anticancer stereoisomer drugs in their pharmaceutical preparations following micellar enhancement: application to kinetic degradation studies Spectrochim Acta Part A Mol Biomol Spectrosc 2016 163 145 153 10.1016/j.saa.2016.03.034
Eman I, El-Yazbi AF. An eco-friendly stability-indicating spectrofluorimetric method for the determination of two anticancer stereoisomer drugs in their pharmaceutical preparations following micellar enhancement: application to kinetic degradation studies. Spectrochim Acta Part A Mol Biomol Spectrosc. 2016;163:145–53.10.1016/j.saa.2016.03.034
16. Derayea SM Ali R Hamad AA Facile one-pot green solvent synergized fluorescence reaction for determination of doxorubicin in presence of paclitaxel; co-administered drug, application to stability study and analysis in bulk, vial and biological fluids Arab J Chem 2020 13 11 8026 8038 10.1016/j.arabjc.2020.09.032
Derayea SM, Ali R, Hamad AA. Facile one-pot green solvent synergized fluorescence reaction for determination of doxorubicin in presence of paclitaxel; co-administered drug, application to stability study and analysis in bulk, vial and biological fluids. Arab J Chem. 2020;13(11):8026–38.10.1016/j.arabjc.2020.09.032
17. Tolba M Salim M Inclusive study for segregation of two commonly used anticancer drugs with tramadol: applying a green fluorimetric strategy to pharmaceutical dosage forms and human plasma Microchem J 2021 162 105859 10.1016/j.microc.2020.105859
Tolba M, Salim M. Inclusive study for segregation of two commonly used anticancer drugs with tramadol: applying a green fluorimetric strategy to pharmaceutical dosage forms and human plasma. Microchem J. 2021;162: 105859.10.1016/j.microc.2020.105859
18. Skalová Š Langmaier J Barek J Vyskočil V Navrátil T Doxorubicin determination using two novel voltammetric approaches: a comparative study Electrochim Acta 2020 330 135180 10.1016/j.electacta.2019.135180
Skalová Š, Langmaier J, Barek J, Vyskočil V, Navrátil T. Doxorubicin determination using two novel voltammetric approaches: a comparative study. Electrochim Acta. 2020;330: 135180.10.1016/j.electacta.2019.135180
19. Hahn Y Lee HY Electrochemical behavior and square wave voltammetric determination of doxorubicin hydrochloride Arch Pharmacal Res 2004 27 31 34 10.1007/BF02980041
Hahn Y, Lee HY. Electrochemical behavior and square wave voltammetric determination of doxorubicin hydrochloride. Arch Pharmacal Res. 2004;27:31–4.10.1007/BF02980041
20. Vajdle O Zbiljić J Tasić B Jović D Guzsvány V Djordjevic A Voltammetric behavior of doxorubicin at a renewable silver-amalgam film electrode and its determination in human urine Electrochim Acta 2014 132 49 57 10.1016/j.electacta.2014.03.124
Vajdle O, Zbiljić J, Tasić B, Jović D, Guzsvány V, Djordjevic A. Voltammetric behavior of doxorubicin at a renewable silver-amalgam film electrode and its determination in human urine. Electrochim Acta. 2014;132:49–57.10.1016/j.electacta.2014.03.124
21. Stanić Z Curcumin, a compound from natural sources, a true scientific challenge—a review Plant Foods Hum Nutr 2017 72 1 12 10.1007/s11130-016-0590-1 27995378
Stanić Z. Curcumin, a compound from natural sources, a true scientific challenge—a review. Plant Foods Hum Nutr. 2017;72:1–12.27995378 10.1007/s11130-016-0590-1
22. Wang X Chang X Zhan H Zhang Q Li C Gao Q Curcumin and Baicalin ameliorate ethanol-induced liver oxidative damage via the Nrf2/HO-1 pathway J Food Biochem 2020 44 10 e13425 10.1111/jfbc.13425 32770697
Wang X, Chang X, Zhan H, Zhang Q, Li C, Gao Q, et al. Curcumin and Baicalin ameliorate ethanol-induced liver oxidative damage via the Nrf2/HO-1 pathway. J Food Biochem. 2020;44(10): e13425.32770697 10.1111/jfbc.13425
23. Ba P Xu M Yu M Li L Duan X Lv S Curcumin suppresses the proliferation and tumorigenicity of Cal27 by modulating cancer-associated fibroblasts of TSCC Oral Dis 2020 26 7 1375 1383 10.1111/odi.13306 32060973
Ba P, Xu M, Yu M, Li L, Duan X, Lv S, et al. Curcumin suppresses the proliferation and tumorigenicity of Cal27 by modulating cancer-associated fibroblasts of TSCC. Oral Dis. 2020;26(7):1375–83.32060973 10.1111/odi.13306
24. Al-Dossari MH Fadda LM Attia HA Hasan IH Mahmoud AM Curcumin and selenium prevent lipopolysaccharide/diclofenac-induced liver injury by suppressing inflammation and oxidative stress Biol Trace Elem Res 2020 196 173 183 10.1007/s12011-019-01910-4 31654258
Al-Dossari MH, Fadda LM, Attia HA, Hasan IH, Mahmoud AM. Curcumin and selenium prevent lipopolysaccharide/diclofenac-induced liver injury by suppressing inflammation and oxidative stress. Biol Trace Elem Res. 2020;196:173–83.31654258 10.1007/s12011-019-01910-4
25. Abo-Zaid MA Shaheen ES Ismail AH Immunomodulatory effect of curcumin on hepatic cirrhosis in experimental rats J Food Biochem 2020 44 6 e13219 10.1111/jfbc.13219 32215945
Abo-Zaid MA, Shaheen ES, Ismail AH. Immunomodulatory effect of curcumin on hepatic cirrhosis in experimental rats. J Food Biochem. 2020;44(6): e13219.32215945 10.1111/jfbc.13219
26. Sudirman S Lai C-S Yan Y-L Yeh H-I Kong Z-L Histological evidence of chitosan-encapsulated curcumin suppresses heart and kidney damages on streptozotocin-induced type-1 diabetes in mice model Sci Rep 2019 9 1 15233 10.1038/s41598-019-51821-6 31645652
Sudirman S, Lai C-S, Yan Y-L, Yeh H-I, Kong Z-L. Histological evidence of chitosan-encapsulated curcumin suppresses heart and kidney damages on streptozotocin-induced type-1 diabetes in mice model. Sci Rep. 2019;9(1):15233.31645652 10.1038/s41598-019-51821-6
27. Nayak D Tripathi N Kathuria D Siddharth S Nayak A Bharatam PV Quinacrine and curcumin synergistically increased the breast cancer stem cells death by inhibiting ABCG2 and modulating DNA damage repair pathway Int J Biochem Cell Biol 2020 119 105682 10.1016/j.biocel.2019.105682 31877386
Nayak D, Tripathi N, Kathuria D, Siddharth S, Nayak A, Bharatam PV, et al. Quinacrine and curcumin synergistically increased the breast cancer stem cells death by inhibiting ABCG2 and modulating DNA damage repair pathway. Int J Biochem Cell Biol. 2020;119: 105682.31877386 10.1016/j.biocel.2019.105682
28. Li J Jiang Y Wen J Fan G Wu Y Zhang C A rapid and simple HPLC method for the determination of curcumin in rat plasma: assay development, validation and application to a pharmacokinetic study of curcumin liposome Biomed Chromatogr 2009 23 11 1201 1207 10.1002/bmc.1244 19488971
Li J, Jiang Y, Wen J, Fan G, Wu Y, Zhang C. A rapid and simple HPLC method for the determination of curcumin in rat plasma: assay development, validation and application to a pharmacokinetic study of curcumin liposome. Biomed Chromatogr. 2009;23(11):1201–7.19488971 10.1002/bmc.1244
29. Syed HK Liew KB Loh GOK Peh KK Stability indicating HPLC–UV method for detection of curcumin in Curcuma longa extract and emulsion formulation Food Chem 2015 170 321 326 10.1016/j.foodchem.2014.08.066 25306352
Syed HK, Liew KB, Loh GOK, Peh KK. Stability indicating HPLC–UV method for detection of curcumin in Curcuma longa extract and emulsion formulation. Food Chem. 2015;170:321–6.25306352 10.1016/j.foodchem.2014.08.066
30. Sharma K Agrawal S Gupta M Development and validation of UV spectrophotometric method for the estimation of curcumin in bulk drug and pharmaceutical dosage forms Int J Drug Dev Res 2012 4 2 375 380
Sharma K, Agrawal S, Gupta M. Development and validation of UV spectrophotometric method for the estimation of curcumin in bulk drug and pharmaceutical dosage forms. Int J Drug Dev Res. 2012;4(2):375–80.
31. Jasim F Ali F A novel method for the spectrophotometric determination of curcumin and its application to curcumin spices Microchem J 1988 38 1 106 110 10.1016/0026-265X(88)90008-2
Jasim F, Ali F. A novel method for the spectrophotometric determination of curcumin and its application to curcumin spices. Microchem J. 1988;38(1):106–10.10.1016/0026-265X(88)90008-2
32. Sravani AB Mathew EM Ghate V Lewis SA A sensitive spectrofluorimetric method for curcumin analysis J Fluoresc 2022 32 4 1517 1527 10.1007/s10895-022-02947-w 35526207
Sravani AB, Mathew EM, Ghate V, Lewis SA. A sensitive spectrofluorimetric method for curcumin analysis. J Fluoresc. 2022;32(4):1517–27.35526207 10.1007/s10895-022-02947-w
33. Karimi M Mashreghi M Shokooh Saremi S Jaafari MR Spectrofluorometric method development and validation for the determination of curcumin in nanoliposomes and plasma J Fluoresc 2020 30 1113 1119 10.1007/s10895-020-02574-3 32643044
Karimi M, Mashreghi M, Shokooh Saremi S, Jaafari MR. Spectrofluorometric method development and validation for the determination of curcumin in nanoliposomes and plasma. J Fluoresc. 2020;30:1113–9.32643044 10.1007/s10895-020-02574-3
34. El Sharkasy ME Aboshabana R Belal F Walash M Tolba MM Synchronized spectrofluorimetric determination of ponatinib and curcumin as an effective therapeutic combination in laboratory prepared mixtures and human plasma samples Spectrochim Acta Part A Mol Biomol Spectrosc 2022 264 120235 10.1016/j.saa.2021.120235
El Sharkasy ME, Aboshabana R, Belal F, Walash M, Tolba MM. Synchronized spectrofluorimetric determination of ponatinib and curcumin as an effective therapeutic combination in laboratory prepared mixtures and human plasma samples. Spectrochim Acta Part A Mol Biomol Spectrosc. 2022;264: 120235.10.1016/j.saa.2021.120235
35. Magdy G Radwan AS Belal F El-Deen AK Simple and affordable synchronous spectrofluorimetric determination of the natural anticancer polyphenols; resveratrol and curcumin in human plasma Spectrochim Acta Part A Mol Biomol Spectrosc 2023 302 123029 10.1016/j.saa.2023.123029
Magdy G, Radwan AS, Belal F, El-Deen AK. Simple and affordable synchronous spectrofluorimetric determination of the natural anticancer polyphenols; resveratrol and curcumin in human plasma. Spectrochim Acta Part A Mol Biomol Spectrosc. 2023;302: 123029.10.1016/j.saa.2023.123029
36. Ziyatdinova G Nizamova A Budnikov H Voltammetric determination of curcumin in spices J Anal Chem 2012 67 591 594 10.1134/S1061934812040132
Ziyatdinova G, Nizamova A, Budnikov H. Voltammetric determination of curcumin in spices. J Anal Chem. 2012;67:591–4.10.1134/S1061934812040132
37. Pushpanjali PA Manjunatha JG Amrutha BM Hareesha N Development of carbon nanotube-based polymer-modified electrochemical sensor for the voltammetric study of Curcumin Mater Res Innov 2021 25 7 412 420 10.1080/14328917.2020.1842589
Pushpanjali PA, Manjunatha JG, Amrutha BM, Hareesha N. Development of carbon nanotube-based polymer-modified electrochemical sensor for the voltammetric study of Curcumin. Mater Res Innov. 2021;25(7):412–20.10.1080/14328917.2020.1842589
38. Chaisiwamongkhol K Ngamchuea K Batchelor-McAuley C Compton RG Multiwalled carbon nanotube modified electrodes for the adsorptive stripping voltammetric determination and quantification of curcumin in turmeric Electroanalysis 2017 29 4 1049 1055 10.1002/elan.201600670
Chaisiwamongkhol K, Ngamchuea K, Batchelor-McAuley C, Compton RG. Multiwalled carbon nanotube modified electrodes for the adsorptive stripping voltammetric determination and quantification of curcumin in turmeric. Electroanalysis. 2017;29(4):1049–55.10.1002/elan.201600670
39. Ashrafizadeh M Zarrabi A Hashemi F Zabolian A Saleki H Bagherian M Polychemotherapy with curcumin and doxorubicin via biological nanoplatforms: enhancing antitumor activity Pharmaceutics 2020 12 11 1084 10.3390/pharmaceutics12111084 33187385
Ashrafizadeh M, Zarrabi A, Hashemi F, Zabolian A, Saleki H, Bagherian M, et al. Polychemotherapy with curcumin and doxorubicin via biological nanoplatforms: enhancing antitumor activity. Pharmaceutics. 2020;12(11):1084.33187385 10.3390/pharmaceutics12111084
40. Hashemi M Ebrahimian M Recent advances in nanoformulations for co-delivery of curcumin and chemotherapeutic drugs Nanomed J 2017 4 1 1 7
Hashemi M, Ebrahimian M. Recent advances in nanoformulations for co-delivery of curcumin and chemotherapeutic drugs. Nanomed J. 2017;4(1):1–7.
41. Ma W Wang J Guo Q Tu P Simultaneous determination of doxorubicin and curcumin in rat plasma by LC–MS/MS and its application to pharmacokinetic study J Pharm Biomed Anal 2015 111 215 221 10.1016/j.jpba.2015.04.007 25910045
Ma W, Wang J, Guo Q, Tu P. Simultaneous determination of doxorubicin and curcumin in rat plasma by LC–MS/MS and its application to pharmacokinetic study. J Pharm Biomed Anal. 2015;111:215–21.25910045 10.1016/j.jpba.2015.04.007
42. Wang J Li Y Ma W Wang X Tu P Validated LC–MS/MS method for simultaneous determination of doxorubicin and curcumin in polymeric micelles in subcellular compartments of MCF-7/Adr cells by protein precipitation–ultrasonic breaking method Biomed Chromatogr 2017 31 6 e3892 10.1002/bmc.3892
Wang J, Li Y, Ma W, Wang X, Tu P. Validated LC–MS/MS method for simultaneous determination of doxorubicin and curcumin in polymeric micelles in subcellular compartments of MCF-7/Adr cells by protein precipitation–ultrasonic breaking method. Biomed Chromatogr. 2017;31(6): e3892.10.1002/bmc.3892
43. Abd-AlGhafar WN Aly F Sheribah ZA Saad S Synchronous fluorescence as a green and selective method for the simultaneous determination of cetirizine and azelastine in aqueous humor J Fluoresc 2022 32 1199 1210 10.1007/s10895-022-02913-6 35344122
Abd-AlGhafar WN, Aly F, Sheribah ZA, Saad S. Synchronous fluorescence as a green and selective method for the simultaneous determination of cetirizine and azelastine in aqueous humor. J Fluoresc. 2022;32:1199–210.35344122 10.1007/s10895-022-02913-6
44. Abo Shabana R Elmansi H Ibrahim F Utility of synchronous fluorimetry for the concurrent quantitation of metoprolol and ivabradine Spectrochim Acta Part A Mol Biomol Spectrosc 2022 280 121482 10.1016/j.saa.2022.121482
Abo Shabana R, Elmansi H, Ibrahim F. Utility of synchronous fluorimetry for the concurrent quantitation of metoprolol and ivabradine. Spectrochim Acta Part A Mol Biomol Spectrosc. 2022;280: 121482.10.1016/j.saa.2022.121482
45. Abo El Abass S Elmansi H Synchronous fluorescence as a green and selective tool for simultaneous determination of bambuterol and its main degradation product, terbutaline R Soc Open Sci 2018 5 10 181359 10.1098/rsos.181359 30473864
Abo El Abass S, Elmansi H. Synchronous fluorescence as a green and selective tool for simultaneous determination of bambuterol and its main degradation product, terbutaline. R Soc Open Sci. 2018;5(10): 181359.30473864 10.1098/rsos.181359
46. Yosrey E Elmansi H Sheribah ZA Metwally MES Micellar-emphasized simultaneous determination of ivabradine hydrochloride and felodipine using synchronous spectrofluorimetry Lumin J Biol Chem Lumin 2022 37 4 569 576 10.1002/bio.4187
Yosrey E, Elmansi H, Sheribah ZA, Metwally MES. Micellar-emphasized simultaneous determination of ivabradine hydrochloride and felodipine using synchronous spectrofluorimetry. Lumin J Biol Chem Lumin. 2022;37(4):569–76.10.1002/bio.4187
47. Abo Elkheir SM Zeid AM Nasr JJM Walash MI First derivative synchronous spectrofluorimetric analysis of bisoprolol fumarate and ivabradine in pharmaceutical and biological matrices. Investigation of the method greenness Lumin J Biol Chem Lumin 2022 37 10 1657 1665 10.1002/bio.4337
Abo Elkheir SM, Zeid AM, Nasr JJM, Walash MI. First derivative synchronous spectrofluorimetric analysis of bisoprolol fumarate and ivabradine in pharmaceutical and biological matrices. Investigation of the method greenness. Lumin J Biol Chem Lumin. 2022;37(10):1657–65.10.1002/bio.4337
48. Keith LH Gron LU Young JL Green analytical methodologies Chem Rev 2007 107 6 2695 2708 10.1021/cr068359e 17521200
Keith LH, Gron LU, Young JL. Green analytical methodologies. Chem Rev. 2007;107(6):2695–708.17521200 10.1021/cr068359e
49. Gałuszka A Migaszewski ZM Konieczka P Namieśnik J Analytical eco-scale for assessing the greenness of analytical procedures TrAC Trends Anal Chem 2012 37 61 72 10.1016/j.trac.2012.03.013
Gałuszka A, Migaszewski ZM, Konieczka P, Namieśnik J. Analytical eco-scale for assessing the greenness of analytical procedures. TrAC Trends Anal Chem. 2012;37:61–72.10.1016/j.trac.2012.03.013
50. Pena-Pereira F Wojnowski W Tobiszewski M AGREE—Analytical GREEnness metric approach and software Anal Chem 2020 92 14 10076 10082 10.1021/acs.analchem.0c01887 32538619
Pena-Pereira F, Wojnowski W, Tobiszewski M. AGREE—Analytical GREEnness metric approach and software. Anal Chem. 2020;92(14):10076–82.32538619 10.1021/acs.analchem.0c01887
51. Mostafa AM Rageh AH Ali MF Mohamed FA Micelle and inclusion complex enhanced spectrofluorimetric methods for determination of Retigabine: application in pharmaceutical and biological analysis Spectrochim Acta Part A Mol Biomol Spectrosc 2019 207 251 261 10.1016/j.saa.2018.09.030
Mostafa AM, Rageh AH, Ali MF, Mohamed FA. Micelle and inclusion complex enhanced spectrofluorimetric methods for determination of Retigabine: application in pharmaceutical and biological analysis. Spectrochim Acta Part A Mol Biomol Spectrosc. 2019;207:251–61.10.1016/j.saa.2018.09.030
52. Guideline ICH. Validation of analytical procedures: text and methodology. Q2 (R1). 2005;1(20):05.
53. Miller J Miller JC Statistics and chemometrics for analytical chemistry 2018 Harlow Pearson Education
Miller J, Miller JC. Statistics and chemometrics for analytical chemistry. Harlow: Pearson Education; 2018.
54. Maliszewska O Plenis A Olędzka I Kowalski P Miękus N Bień E Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies J Pharm Biomed Anal 2018 158 376 385 10.1016/j.jpba.2018.06.031 29936377
Maliszewska O, Plenis A, Olędzka I, Kowalski P, Miękus N, Bień E, et al. Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies. J Pharm Biomed Anal. 2018;158:376–85.29936377 10.1016/j.jpba.2018.06.031
55. Heath DD Pruitt MA Brenner DE Rock CL Curcumin in plasma and urine: quantitation by high-performance liquid chromatography J Chromatogr B 2003 783 1 287 295 10.1016/S1570-0232(02)00714-6
Heath DD, Pruitt MA, Brenner DE, Rock CL. Curcumin in plasma and urine: quantitation by high-performance liquid chromatography. J Chromatogr B. 2003;783(1):287–95.10.1016/S1570-0232(02)00714-6
